Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Lab
- PDF / 214,545 Bytes
- 1 Pages / 595.276 x 790.866 pts Page_size
- 71 Downloads / 239 Views
CORRECTION
Correction to: The Effect of Rifampin on the Pharmacokinetics and Safety of Lorlatinib: Results of a Phase One, Open-Label, Crossover Study in Healthy Participants Joseph Chen
. Huiping Xu . Sylvester Pawlak . Leonard P. James .
Gerson Peltz . Kimberly Lee . Katherine Ginman . Michelle Bergeron . Yazdi K. Pithavala
Ó Springer Healthcare Ltd., part of Springer Nature 2020
Correction to: Adv Ther (2020) 37:745–758 https://doi.org/10.1007/s12325019-01198-9 In the original article, the reference 4 has been published and cited incorrectly. The correct reference 4 is ‘‘LorbrenaÒ (lorlatinib) tablets. [Prescribing Information]. Pfizer Labs’’. Additionally, reference 4 was cited in error in the Discussion section of the original article (page The original article can be found online at https://doi. org/10.1007/s12325-019-01198-9. J. Chen (&) L. P. James Global Product Development, Pfizer Oncology, New York, NY, USA e-mail: [email protected] H. Xu Y. K. Pithavala Global Product Development, Clinical Pharmacology, Pfizer Oncology, La Jolla, CA, USA S. Pawlak Global Product Development, Pfizer Inc., New Haven, CT, USA G. Peltz Safety Surveillance and Risk Management, Pfizer Oncology, Groton, CT, USA K. Lee M. Bergeron Global Product Development, Pfizer Inc., Groton, CT, USA K. Ginman Global Product Development, Pfizer Inc., South Lyon, MI, USA
755, column 2, paragraph 2, sentence 1). The corrected sentence is as follows: ‘‘When used in drug-drug interaction studies to elicit metabolic induction, a rifampin dose of 600 mg/day is typically not associated with transaminase elevations [7, 10].’’
Data Loading...
